- Home
- CPF vs PRAX Comparison
CPF vs PRAX Comparison
Compare CPF & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPF
- PRAX
- Stock Information
- Founded
- CPF 1954
- PRAX 2015
- Country
- CPF United States
- PRAX United States
- Employees
- CPF N/A
- PRAX N/A
- Industry
- CPF Major Banks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- CPF Finance
- PRAX Health Care
- Exchange
- CPF Nasdaq
- PRAX Nasdaq
- Market Cap
- CPF 714.5M
- PRAX 599.7M
- IPO Year
- CPF N/A
- PRAX 2020
- Fundamental
- Price
- CPF $26.78
- PRAX $38.25
- Analyst Decision
- CPF Buy
- PRAX Strong Buy
- Analyst Count
- CPF 1
- PRAX 10
- Target Price
- CPF $30.00
- PRAX $116.50
- AVG Volume (30 Days)
- CPF 164.5K
- PRAX 461.1K
- Earning Date
- CPF 04-23-2025
- PRAX 05-02-2025
- Dividend Yield
- CPF 4.01%
- PRAX N/A
- EPS Growth
- CPF 4.40
- PRAX N/A
- EPS
- CPF 2.14
- PRAX N/A
- Revenue
- CPF $247,706,000.00
- PRAX $8,122,000.00
- Revenue This Year
- CPF N/A
- PRAX N/A
- Revenue Next Year
- CPF $17.75
- PRAX $789.73
- P/E Ratio
- CPF $12.57
- PRAX N/A
- Revenue Growth
- CPF 5.37
- PRAX 270.02
- 52 Week Low
- CPF $19.52
- PRAX $26.70
- 52 Week High
- CPF $33.25
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- CPF 57.75
- PRAX 54.88
- Support Level
- CPF $25.23
- PRAX $34.89
- Resistance Level
- CPF $27.10
- PRAX $40.89
- Average True Range (ATR)
- CPF 0.83
- PRAX 2.30
- MACD
- CPF 0.19
- PRAX 0.74
- Stochastic Oscillator
- CPF 50.91
- PRAX 68.87
About CPF Central Pacific Financial Corp New
Central Pacific Financial Corp operates in the financial services sector in the United States. It is a full-service commercial bank offering a broad range of banking products and services, including accepting time and demand deposits and originating loans. Bank's deposits are insured by the Federal Deposit Insurance Corporation (FDIC) up to applicable limits. The bank is not a member of the Federal Reserve System. The company's loans include commercial loans, construction loans, commercial and residential mortgage loans, and consumer loans. The company derives income from interest and fees on loans, interest on investment securities, and fees received in connection with deposits and other services.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.